SI-BONE, Inc. (NASDAQ:SIBN) Given Average Rating of “Buy” by Analysts

SI-BONE, Inc. (NASDAQ:SIBNGet Free Report) has earned an average recommendation of “Buy” from the six ratings firms that are covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $23.00.

Several analysts have weighed in on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $19.00 target price on shares of SI-BONE in a research note on Wednesday, November 20th. Truist Financial lifted their target price on SI-BONE from $16.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th.

Read Our Latest Research Report on SIBN

Insider Transactions at SI-BONE

In other news, CEO Laura Francis sold 10,048 shares of the business’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $12.58, for a total transaction of $126,403.84. Following the sale, the chief executive officer now directly owns 482,875 shares of the company’s stock, valued at $6,074,567.50. The trade was a 2.04 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Anshul Maheshwari sold 2,439 shares of the business’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $12.68, for a total value of $30,926.52. Following the sale, the chief financial officer now directly owns 194,623 shares in the company, valued at $2,467,819.64. This trade represents a 1.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 21,679 shares of company stock valued at $276,439. Corporate insiders own 3.90% of the company’s stock.

Institutional Investors Weigh In On SI-BONE

Institutional investors and hedge funds have recently modified their holdings of the stock. Millrace Asset Group Inc. acquired a new stake in shares of SI-BONE during the third quarter worth $1,056,000. Champlain Investment Partners LLC raised its position in shares of SI-BONE by 14.7% during the third quarter. Champlain Investment Partners LLC now owns 2,800,073 shares of the company’s stock worth $39,145,000 after purchasing an additional 358,821 shares during the period. Impax Asset Management Group plc raised its position in shares of SI-BONE by 41.3% during the third quarter. Impax Asset Management Group plc now owns 758,521 shares of the company’s stock worth $10,604,000 after purchasing an additional 221,604 shares during the period. American Century Companies Inc. raised its position in shares of SI-BONE by 22.8% during the second quarter. American Century Companies Inc. now owns 1,986,476 shares of the company’s stock worth $25,685,000 after purchasing an additional 368,637 shares during the period. Finally, Divisadero Street Capital Management LP purchased a new position in shares of SI-BONE during the second quarter valued at $1,552,000. 98.11% of the stock is owned by institutional investors and hedge funds.

SI-BONE Stock Up 0.5 %

Shares of SI-BONE stock opened at $13.84 on Wednesday. The business’s fifty day moving average price is $13.40 and its two-hundred day moving average price is $14.10. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22. The company has a market capitalization of $580.42 million, a P/E ratio of -15.04 and a beta of 1.20. SI-BONE has a 1-year low of $11.70 and a 1-year high of $21.70.

About SI-BONE

(Get Free Report

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.

See Also

Analyst Recommendations for SI-BONE (NASDAQ:SIBN)

Receive News & Ratings for SI-BONE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-BONE and related companies with MarketBeat.com's FREE daily email newsletter.